Cost-Effectiveness Analysis of the Bivalent Compared with the Quadrivalent Human Papillomavirus Vaccines in Taiwan

Demarteau, Nadia; Tang, Chao Hsiun; Chen, Hui Chi; Chen, Chien Jen; Kriekinge, Georges Van

doi:10.1016/j.jval.2012.02.012

Cited by 21 publications

(25 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the quadrivalent vaccine was more favorable if anogenital warts cases were included in the analysis (ICER e16,300/QALY). These results are in line with the results from various other studies [55,56], which mentioned that mass HPV vaccination with the quadrivalent vaccine was slightly dominated by the bivalent vaccine. However, long-term results on crossprotection have yet to be provided.…”

Section: Discussion and Limitationsupporting

confidence: 92%

The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective

Setiawan

Luttjeboer

Westra

et al. 2014

Expert Review of Vaccines

View full text Add to dashboard Cite

Addition of the HPV vaccine to available cytological screening has been proposed to increase HPV-related cancer prevention. A comprehensive review on this combined strategy implemented in the Netherlands is lacking. For this review, we therefore analyzed all relevant studies on cost-effectiveness of HPV vaccines in combination with cervical screening in the Netherlands. Most of the studies agree that vaccination in pre-sexual-activity periods of life is cost-effective. Based on published sensitivity analyses, the incremental cost-effectiveness ratio was found to be mainly driven by vaccine cost and discount rates. Fewer vaccine doses, inclusion of additional benefits of these vaccines to prevent HPV-related non-cervical cancers and vaccination of males to further reduce the burden of HPV-induced cancers are three relevant options suggested to be investigated in upcoming economic evaluations.

show abstract

Section: Discussion and Limitationsupporting

confidence: 92%

The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective

Setiawan

Luttjeboer

Westra

et al. 2014

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…Through the implementation of a national policy to support vaccination of socially vulnerable populations rather than the general population, we expect to see a decrease in the economic burden caused by HPV infections (Liao et al, 2009;Demarteau et al, 2012;da Fonseca et al, 2013). Of course, it is difficult to determine the actual economic value of HPV vaccination from the results of this study; thus, further studies should be undertaken.…”

Section: Discussionmentioning

confidence: 94%

Cost-Effectiveness Analysis of HPV Vaccination: Comparing the General Population with Socially Vulnerable Individuals

Han

Kim

Lee

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: After the WHO recommended HPV vaccination of the general population in 2009, government support of HPV vaccination programs was increased in many countries. However, this policy was not implemented in Korea due to perceived low cost-effectiveness. Thus, the aim of this study was to analyze the cost-utility of HPV vaccination programs targeted to high risk populations as compared to vaccination programs for the general population. Materials and Methods: Each study population was set to 100,000 people in a simulation study to determine the incremental cost-utility ratio (ICUR), then standard prevalence rates, cost, vaccination rates, vaccine efficacy, and the Quality-Adjusted Life-Years (QALYs) were applied to the analysis. In addition,

show abstract

“…2 Input parameters and assumptions were retrieved from the literature, public databases and expert opinion. Clinically, the protection offered by the 3-and 2-dose bHPV schedules against HPV-16 and HPV-18 was assumed to be identical based on clinical trial results and set at 98% for both vaccines.…”

Section: Model Structure and Input Datamentioning

confidence: 99%

“…HPV-31/33/35/39/45/51/52/56/58/59, see Table 1 for details). 2 The quality of life detriment for each endpoint used in the model is reported in Table 1. A lifelong duration and a 2-dose vaccination schedule were assumed for each vaccine and the same price per dose at £80.50.…”

Section: Model Structure and Input Datamentioning

confidence: 99%

“…trivalent flu vaccine), the profiles of bHPV and qHPV differ markedly, which has triggered comparative assessment on costs and benefits of the two vaccines. 2 In the UK, the HPV vaccination programme started in 2008 using the bHPV. In 2011, the UK government changed the criteria for the tender renewal, which led to GSK not submitting for the tender.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Does it matter? Discounting and its role in the cost-effectiveness of preventative interventions. The case of HPV vaccination

Camejo¹,

Li²,

Kriekinge³

2015

Public Health

View full text Add to dashboard Cite

Cost-Effectiveness Analysis of the Bivalent Compared with the Quadrivalent Human Papillomavirus Vaccines in Taiwan

Abstract: Both vaccines have a different epidemiological impact with an increased number of CC-related lesions potentially prevented for the BV because of additional cross-protection. In the Taiwanese setting, HPV mass vaccination using the BV was estimated to dominate vaccination using the QV.

Cited by 21 publications

References 49 publications

The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective

The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective

Cost-Effectiveness Analysis of HPV Vaccination: Comparing the General Population with Socially Vulnerable Individuals

Does it matter? Discounting and its role in the cost-effectiveness of preventative interventions. The case of HPV vaccination

Contact Info

Product

Resources

About